Document Type : Review article


1 Cellular and Molecular Research Center, , Basic Health Sciences Institute, Shahrekord University of Medical Science, Shahrekord, Iran

2 Social Determinants of Health Research Center, Shahrekord University of Medical Science, Shahrekord, Iran


Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS). This highly disabling disorder is characterized by a variable clinical course. MS is a heterogeneous disease with a complex pathology and significant social and economic impact. MS is associated with dysfunction of parts of the nervous system which results in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. There is no definite treatment for MS. Iran has been thought to be located in the low risk zone of MS prevalence. However, recent studies and investigations in some cities such as Isfahan, a central province of Iran, have suggested a medium-to-high risk level of MS prevalence. Pathophysiological processes in MS contribute to the disease course and clinical manifestations. Therefore, biomarkers that are indicators of these events would provide significant potential for diagnosis, prediction of disease course, and optimization of therapeutic responses. This review provides information on the prevalence of MS and some risk factors among Iranian people.


1.Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Hamidian Jahromi A, Aghighi M, et al. Significant increase in the prevalence of multiple sclerosis in iran in 2011. Iran J Med Sci. 2014;39(2):152-3. 
2.Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012;5(1):13-22. doi: 10.1177/1756285611425694. 
3.Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17. doi: 10.1016/S0140- 6 7 3 6 ( 0 8 ) 6 1 6 2 0 - 7 .
4.Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S. The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol. 2015;127-128:1-22. doi: 10.1016/j.pneurobio.2015.02.003. 
5.Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288-99. doi: 10.1002/ana.21117. 
6.Zhang P, Wang R, Li Z, Wang Y, Gao C, Lv X, et al. The risk of smoking on multiple sclerosis: a meta-analysis based on 20,626 cases from case-control and cohort studies. PeerJ. 2016;4:e1797. doi: 10.7717/peerj.1797. 
7.Ebrahimi HA, Sedighi B. Prevalence of multiple sclerosis and environmental factors in Kerman province, Iran. Neurol Asia. 2013;18(4):385-9. 
8.Habib C, Zheng W, Haacke EM, Webb S, Nichol H. Visualizing Iron Deposition in Multiple Sclerosis Cadaver Brains. American Institute of Physics. 2010;78-83. doi: 10.1063/1.3478203. 
9.Hosking MP, Lane TE. The Biology of Persistent Infection: Inflammation and Demyelination following Murine Coronavirus Infection of the Central Nervous System. Curr Immunol Rev. 2009;5(4):267-76. doi: 10.2174/157339509789504005. 
10.Johnson S. The possible role of gradual accumulation of copper, cadmium, lead and iron and gradual depletion of zinc, magnesium, selenium, vitamins B2, B6, D, and E and essential fatty acids in multiple sclerosis. Med Hypotheses. 2000;55(3):239-41. doi: 10.1054/mehy.2000.1051. 
11.Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61(10):1613-5. doi: 10.1001/archneur.61.10.1613. 
12.Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387-94. doi: 10.1016/j.autrev.2009.11.010. 
13.Ramagopalan SV, Handel AE, Giovannoni G, Rutherford Siegel S, Ebers GC, Chaplin G. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology. 2011;76(16):1410-4. doi: 10.1212/WNL.0b013e318216715e. 
14.Zabihi R, Galehdari H, Shafiee M, Kazeminejad SR, Alavi SM. Analysis of HLA-DQB1*0602 in Multiple Sclerosis Patients in Khuzestan Province, Iran. Arch Iran Med. 2015;18(10):698- 702. doi: 0151810/aim.0010. 
15.Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-9. doi: 10.1038/nature10251. 
16.Tolou-Ghamari Z. A Review of Geoepidemiological Differences of Multiple Sclerosis in Iran and Other Middle East Countries. Arch Neurosci. 2015;2(3):e22028. doi: 10.5812/ archneurosci.22028. 
17.Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun. 2010;34(3):J168-77. doi: 10.1016/j.jaut.2009.11.018. 
18.Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg. 2002;104(3):182- 91. 
19.Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022-4. doi: 10.1212/wnl.0000000000000768. 
20.Aleyasin H, Sarai A, Alaedini F, Ansarian E, Lotfi J. Multiple Sclerosis: A Ssudy of 318 iranian cases. Arch Iran Med. 2002;5(1):24-27. 
21.Bharucha NE, Bharucha EP, Wadia NH, Singhal BS, Bharucha AE, Bhise AV, et al. Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology. 1988;38(5):727-9. 
22.Dean G, Wadia NH. Multiple sclerosis in the Parsis. J Neurol Neurosurg Psychiatry. 1995;58(2):254. 
23.Asgari A, Ostovan VR, Mehrabi F. Epidemiology of Multiple Sclerosis (MS) in Military Personnel : Demographic Study in Iran. Biomed Pharmacol J. 2015;8:105-110. doi: 10.13005/ bpj/565. 
24.Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand. 1975;51(2):137-57. 
25.Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol. 2013;70(5-6):356-63. doi: 10.1159/000355140. 
26.Kurtzke JF. Epidemiologic contributions to multiple sclerosis: an overview. Neurology. 1980;30(7 Pt 2):61-79. 
27.Moghtaderi A, Rakhshanizadeh F, Shahraki-Ibrahimi S. Incidence and prevalence of multiple sclerosis in southeastern Iran. Clin Neurol Neurosurg. 2013;115(3):304-8. doi: 10.1016/j.clineuro.2012.05.032. 
28.Al Tahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif A, Deleu D, et al. Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. Int J Neurosci. 2014;124(9):635-41. doi: 10.3109/00207454.2013.865620. 
29.Akhtar N, Elsetouhy A, Deleu D, Kamran S, AlHail H, Elalamy O, et al. Newly diagnosed multiple sclerosis in state of Qatar. Clin Neurol Neurosurg. 2013;115(8):1333-7. doi: 10.1016/j. clineuro.2012.12.035. 
30.Saei M, Holakouie-Naieni K, Mostafavi E, Sahraian MA, Mahmoodi M, Mansournia MA, et al. Spatial Analysis of Multiple Sclerosis Disease in Tehran Metropolitan Zone, Iran, 2001-2012. Iran J Public Health. 2014;43(5):621-9. 
31.Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology. 2006;27(1):39-44. doi: 10.1159/000094235. 
32.Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol. 2007;79:357-75. doi: 10.1016/s0074-7742(07)79016-5. 
33.Hashemilar M, Savadi-Ouskui D, Farhoudi M, Ayromlou H, Asadollahi A. Multiple sclerosis in East Azerbaijan, North West Iran. Neurol Asia. 2011;16(2):127-31.
34.Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol. 2010;64(6):331-6. doi: 10.1159/000321649. 
35.Rezaali S, Khalilnezhad A, Naser Moghadasi A, Chaibakhsh S, Sahraian MA. Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. Iran J Neurol. 2013;12(4):136-43. 
36.Multiple sclerosis. Mayo Clinic website. https://www. symptoms-causes/syc-20350269. 
37.Asadollahi S, Fakhri M, Heidari K, Zandieh A, Vafaee R, Mansouri B. Cigarette smoking and associated risk of multiple sclerosis in the Iranian population. J Clin Neurosci. 2013;20(12):1747-50. doi: 10.1016/j.jocn.2013.01.018. 
38.Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun. 2011;2:334. doi: 10.1038/ncomms1333. 
39.Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets. 2012;11(5):545-55. 
40.Orton SM, Ramagopalan SV, Para AE, Lincoln MR, Handunnetthi L, Chao MJ, et al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci. 2011;305(1-2):116-20. doi: 10.1016/j.jns.2011.02.032. 
41.Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3(12):709-18. doi: 10.1016/ s1474-4422(04)00933-0. 
42.Niino M, Miyazaki Y, Fukazawa T, Kikuchi S. [Vitamin D and latitude as environmental factors in multiple sclerosis]. Nihon Rinsho. 2014;72(11):1924-9. 
43.Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology. 2007;69(4):381-8. doi: 10.1212/01. wnl.0000268266.50850.48. 
44.Mansouri B, Asadollahi S, Heidari K, Fakhri M, Assarzadegan F, Nazari M, et al. Risk factors for increased multiple sclerosis susceptibility in the Iranian population. J Clin Neurosci. 2014;21(12):2207-11. doi: 10.1016/j.jocn.2014.04.020. 
45.Inshasi J, Thakre M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci. 2011;121(7):393-8. doi: 10.3109/00207454.2011.565893. 
46.Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351-79. doi: 10.1146/annurevbiochem-060308-103103. 
47.Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97. 
48.Lindsay MA. microRNAs and the immune response. Trends Immunol. 2008;29(7):343-51. doi: 10.1016/ 
49.Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Clerici M. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. J Transl Med. 2015;13:148. doi: 10.1186/s12967-015-0504-2. 
50.Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep. 2012;39(5):6219-25. doi: 10.1007/s11033-011- 1441-7. 
51.Sondergaard HB, Hesse D, Krakauer M, Sorensen PS, Sellebjerg F. Differential microRNA expression in blood in multiple sclerosis. Mult Scler. 2013;19(14):1849-57. doi: 10.1177/1352458513490542.